Time to Rethink Cancer Therapy?

In an earlier post, I wondered a bit about the ultimate causes of cancer. For the last several decades cancer has been labeled as a genetic disease, an idea which we have chased with great fervor. Yet, It feels to me sometimes as though the evolving story of the causes of cancer is like a hall of mirrors in an amusement park in that there seems to be an ever receding chain of causal genetic alterations fueling cancer’s inexorable progression.

Science and the 2012 Election with Bill Frezza


Bill Frezza, Columnist, Bio-IT World, General Partner at Adams Capital Management Bio and Contact Info

Chapters: (Advance the marker)

0:37 Will you rate the presidential candidates on science?

7:07 Let's just fund the top rate researchers

12:46 How do you measure success in the War on Cancer

15:48 Nothing has brought us more progress than the free market

17:57 What about the Manhattan Project?

22:14 How do we keep our edge in the world without strong science funding?

27:40 Who is going to fund life science start-ups?

31:55 BioLeap - designing drugs "de novo"

Bill Frezza is a venture capitalist and columnist at Forbes and Bio-IT World. As one can see from the name of his column, "The Skeptical Outsider," Bill is not shy about questioning the status quo. Today we get him to weigh in on the two presidential candidates and how the outcome of the election will affect science funding. Frezza is a free market advocate and feels that we are funding second and third rate research and creating a surplus of science PhD's. We talk about the War on Cancer and compare it to The Manhattan Project. At the end, Bill discusses the venture capital world and his own new venture, BioLeap.

A Grand Awakening: Bill Frezza, Columnist


Bill Frezza, Columnist, Bio-IT World, General Partner at Adams Capital Management Bio and Contact Info

Listen (5:15) Speaking as an outsider

Listen (7:53) Life science needs a grand awakening

Listen (4:13) Physics and math eventually takes over everything

Listen (2:16) What do you say to detractors?

Listen (11:24) PI's and their indentured servants

Bill Frezza is a Boston-based venture capitalist and a regular columnist at Bio-IT World, Forbes, and Real Clear Markets. Calling himself an outsider to the life sciences, Bill penned a column some weeks back "How to Save the Life Sciences from Technological Torpor." I ask him what he means and this leads to a discussion of what he calls a broken industry in need of some math and physics. Bill is not shy with his opinion, so we plan to have him back soon.

Tumor Heterogeneity and Personalized Medicine

My recent blog post, Tumor heterogeneity, revealed…, discussed the New England Journal of Medicine article by Gerlinger and colleagues describing the genetic heterogeneity found both within a patient’s individual tumor nodules and between spatially separate nodules. There has been a substantial amount of discussion of this work and angst about how it might signal the end of personalized medicine even before it really got started.